Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Global Ioversol Market by Type (IOVERSOL 34% INJECTABLE SOLUTION (OPTIRAY 160), IOVERSOL 51% INJECTABLE SOLUTION (OPTIRAY 240), IOVERSOL 64% INJECTABLE SOLUTION (OPTIRAY 300), IOVERSOL 68% INJECTABLE SOLUTION (OPTIRAY 320), IOVERSOL 74% INJECTABLE SOLUTION (OPTIRAY 350)) and by APPLICATION (X-RAY, CT SCAN, BRAIN DISORDERS, BLOOD VESSEL DISORDERS, HEART DISORDERS, OTHERS): Global Opportunity Analysis and Industry Forecast, 2023-2032

A03436

Pages: NA

Charts: NA

Tables: NA

Ioversol is an organoiodine compound, which contains one or more carbon-iodine bonds. It is a radiopaque contrast agent that absorbs X-rays. It allows blood vessels, organs, and other non-bony tissues to be seen more clearly on a CT scan or other radiologic (X-ray) examination. This unique property of ioversol has led to increased application such as in ultrasound scattering and magnetic resonance imaging. It helps to diagnose disorders of the heart, brain, and blood vessels.

Rise in number of accidents and increase in prevalence of bone-related diseases & kidney problems are the key drivers of the global ioversol market. In addition, growth in geriatric population has led to increased orthopedic disorders and cardiovascular disorders, resulting in the development of the X-ray industry, which in turn fuels the market growth. However, overdose of ioversol might lead allergic reaction; breathing problem; swelling of the face, lips, tongue, or throat; and dehydration & dry skin, which restrains the market growth. Increase in spending on healthcare and advancements in X-ray, CT scan, and other radiological & diagnostic examinations are anticipated to provide new opportunities for the market players.

The ioversol market is segmented based on type, application, and geography. On the basis of type, the market is divided into ioversol 34% injectable solution (optiray 160), ioversol 51% injectable solution (optiray 240), ioversol 64% injectable solution (optiray 300), ioversol 68% injectable solution (optiray 320), and ioversol 74% injectable solution (optiray 350). By application, it is categorized into X-ray, CT scan, brain disorders, blood vessel disorders, heart disorders, and others. The report analyzes the market trends in different geographies, which include North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits

  • The report provides an in-depth analysis of the current trends, drivers, and dynamics of the global ioversol market to elucidate the prevailing opportunities and potential investment pockets.
  • It offers qualitative trends and quantitative analysis for the period to assist stakeholders to understand the market scenario.
  • In-depth analysis of the key segments demonstrates the types and applications of ioversol.
  • Competitive intelligence of the industry highlights the business practices followed by key players across geographies.
  • The key players in the market are profiled along with their strategies and developments to understand the competitive outlook of the industry.

 Key Market Segments

  • By Type
    • IOVERSOL 34% INJECTABLE SOLUTION (OPTIRAY 160)
    • IOVERSOL 51% INJECTABLE SOLUTION (OPTIRAY 240)
    • IOVERSOL 64% INJECTABLE SOLUTION (OPTIRAY 300)
    • IOVERSOL 68% INJECTABLE SOLUTION (OPTIRAY 320)
    • IOVERSOL 74% INJECTABLE SOLUTION (OPTIRAY 350)
  • By APPLICATION
    • X-RAY
      • Angiography
      • Urography
      • Tomography
      • Others
    • CT SCAN
    • BRAIN DISORDERS
    • BLOOD VESSEL DISORDERS
    • HEART DISORDERS
    • OTHERS
  • By Region
    • NORTH AMERICA
      • U.S
      • Canada
      • Mexico
    • EUROPE
      • Germany
      • France
      • UK
      • Italy
      • Rest of Europe
    • ASIA-PACIFIC
      • China
      • Japan
      • India
      • Australia
      • Korea
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • Saudi Arabia
      • South Africa
      • Rest of LAMEA

 
Key Market Players

  • Jiangsu Hengrui Medicine Co.
  • China Resources Pharmaceutical (Shanghai) Co.,
  • Stellence Pharmscience Pvt. Ltd.
  • Ultraject
  • Mallinckrodt Pharmaceuticals
  • A.S. Joshi & Company
  • Novalek Pharmaceuticals Pvt. Ltd.
  • HB Ocean
  • Liebel-Flarsheim Company LLC
  • Guerbet

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: IOVERSOL MARKET, BY TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Type

    • 4.2. IOVERSOL 34% INJECTABLE SOLUTION (OPTIRAY 160)

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. IOVERSOL 51% INJECTABLE SOLUTION (OPTIRAY 240)

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. IOVERSOL 64% INJECTABLE SOLUTION (OPTIRAY 300)

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. IOVERSOL 68% INJECTABLE SOLUTION (OPTIRAY 320)

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. IOVERSOL 74% INJECTABLE SOLUTION (OPTIRAY 350)

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

  • CHAPTER 5: IOVERSOL MARKET, BY APPLICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Application

    • 5.2. X-RAY

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

      • 5.2.4. Angiography

        • 5.2.4.1. Market Size and Forecast

      • 5.2.4. Urography

        • 5.2.4.1. Market Size and Forecast

      • 5.2.4. Tomography

        • 5.2.4.1. Market Size and Forecast

      • 5.2.4. Others

        • 5.2.4.1. Market Size and Forecast

    • 5.3. CT SCAN

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. BRAIN DISORDERS

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. BLOOD VESSEL DISORDERS

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. HEART DISORDERS

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

    • 5.7. OTHERS

      • 5.7.1. Key Market Trends, Growth Factors and Opportunities

      • 5.7.2. Market Size and Forecast, By Region

      • 5.7.3. Market Share Analysis, By Country

  • CHAPTER 6: IOVERSOL MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Type

      • 6.2.3. Market Size and Forecast, By Application

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Ioversol Market

        • 6.2.5.1. Market Size and Forecast, By Type
        • 6.2.5.2. Market Size and Forecast, By Application

      • 6.2.6. Canada Ioversol Market

        • 6.2.6.1. Market Size and Forecast, By Type
        • 6.2.6.2. Market Size and Forecast, By Application

      • 6.2.7. Mexico Ioversol Market

        • 6.2.7.1. Market Size and Forecast, By Type
        • 6.2.7.2. Market Size and Forecast, By Application

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Type

      • 6.3.3. Market Size and Forecast, By Application

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Ioversol Market

        • 6.3.5.1. Market Size and Forecast, By Type
        • 6.3.5.2. Market Size and Forecast, By Application

      • 6.3.6. Germany Ioversol Market

        • 6.3.6.1. Market Size and Forecast, By Type
        • 6.3.6.2. Market Size and Forecast, By Application

      • 6.3.7. Italy Ioversol Market

        • 6.3.7.1. Market Size and Forecast, By Type
        • 6.3.7.2. Market Size and Forecast, By Application

      • 6.3.8. Spain Ioversol Market

        • 6.3.8.1. Market Size and Forecast, By Type
        • 6.3.8.2. Market Size and Forecast, By Application

      • 6.3.9. UK Ioversol Market

        • 6.3.9.1. Market Size and Forecast, By Type
        • 6.3.9.2. Market Size and Forecast, By Application

      • 6.3.10. Russia Ioversol Market

        • 6.3.10.1. Market Size and Forecast, By Type
        • 6.3.10.2. Market Size and Forecast, By Application

      • 6.3.11. Rest Of Europe Ioversol Market

        • 6.3.11.1. Market Size and Forecast, By Type
        • 6.3.11.2. Market Size and Forecast, By Application

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Type

      • 6.4.3. Market Size and Forecast, By Application

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Ioversol Market

        • 6.4.5.1. Market Size and Forecast, By Type
        • 6.4.5.2. Market Size and Forecast, By Application

      • 6.4.6. Japan Ioversol Market

        • 6.4.6.1. Market Size and Forecast, By Type
        • 6.4.6.2. Market Size and Forecast, By Application

      • 6.4.7. India Ioversol Market

        • 6.4.7.1. Market Size and Forecast, By Type
        • 6.4.7.2. Market Size and Forecast, By Application

      • 6.4.8. South Korea Ioversol Market

        • 6.4.8.1. Market Size and Forecast, By Type
        • 6.4.8.2. Market Size and Forecast, By Application

      • 6.4.9. Australia Ioversol Market

        • 6.4.9.1. Market Size and Forecast, By Type
        • 6.4.9.2. Market Size and Forecast, By Application

      • 6.4.10. Thailand Ioversol Market

        • 6.4.10.1. Market Size and Forecast, By Type
        • 6.4.10.2. Market Size and Forecast, By Application

      • 6.4.11. Malaysia Ioversol Market

        • 6.4.11.1. Market Size and Forecast, By Type
        • 6.4.11.2. Market Size and Forecast, By Application

      • 6.4.12. Indonesia Ioversol Market

        • 6.4.12.1. Market Size and Forecast, By Type
        • 6.4.12.2. Market Size and Forecast, By Application

      • 6.4.13. Rest of Asia Pacific Ioversol Market

        • 6.4.13.1. Market Size and Forecast, By Type
        • 6.4.13.2. Market Size and Forecast, By Application

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Type

      • 6.5.3. Market Size and Forecast, By Application

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Ioversol Market

        • 6.5.5.1. Market Size and Forecast, By Type
        • 6.5.5.2. Market Size and Forecast, By Application

      • 6.5.6. South Africa Ioversol Market

        • 6.5.6.1. Market Size and Forecast, By Type
        • 6.5.6.2. Market Size and Forecast, By Application

      • 6.5.7. Saudi Arabia Ioversol Market

        • 6.5.7.1. Market Size and Forecast, By Type
        • 6.5.7.2. Market Size and Forecast, By Application

      • 6.5.8. UAE Ioversol Market

        • 6.5.8.1. Market Size and Forecast, By Type
        • 6.5.8.2. Market Size and Forecast, By Application

      • 6.5.9. Argentina Ioversol Market

        • 6.5.9.1. Market Size and Forecast, By Type
        • 6.5.9.2. Market Size and Forecast, By Application

      • 6.5.10. Rest of LAMEA Ioversol Market

        • 6.5.10.1. Market Size and Forecast, By Type
        • 6.5.10.2. Market Size and Forecast, By Application

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning, 2024

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Liebel-Flarsheim Company LLC

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Guerbet

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Jiangsu Hengrui Medicine Co.

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Mallinckrodt Pharmaceuticals

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Ultraject

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. China Resources Pharmaceutical (Shanghai) Co.,

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. HB Ocean

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Novalek Pharmaceuticals Pvt. Ltd.

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Stellence Pharmscience Pvt. Ltd.

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. A.S. Joshi And Company

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL IOVERSOL MARKET, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL IOVERSOL MARKET FOR IOVERSOL 34% INJECTABLE SOLUTION (OPTIRAY 160), BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL IOVERSOL MARKET FOR IOVERSOL 51% INJECTABLE SOLUTION (OPTIRAY 240), BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL IOVERSOL MARKET FOR IOVERSOL 64% INJECTABLE SOLUTION (OPTIRAY 300), BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL IOVERSOL MARKET FOR IOVERSOL 68% INJECTABLE SOLUTION (OPTIRAY 320), BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL IOVERSOL MARKET FOR IOVERSOL 74% INJECTABLE SOLUTION (OPTIRAY 350), BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL IOVERSOL MARKET, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL IOVERSOL MARKET FOR X-RAY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL IOVERSOL MARKET FOR CT SCAN, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL IOVERSOL MARKET FOR BRAIN DISORDERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL IOVERSOL MARKET FOR BLOOD VESSEL DISORDERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL IOVERSOL MARKET FOR HEART DISORDERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL IOVERSOL MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. GLOBAL IOVERSOL MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. NORTH AMERICA IOVERSOL, BY REGION, 2025-2033 ($MILLION)
  • TABLE 16. NORTH AMERICA IOVERSOL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 17. NORTH AMERICA IOVERSOL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 18. U.S. IOVERSOL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 19. U.S. IOVERSOL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 20. CANADA IOVERSOL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 21. CANADA IOVERSOL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 22. MEXICO IOVERSOL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 23. MEXICO IOVERSOL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 24. EUROPE IOVERSOL, BY REGION, 2025-2033 ($MILLION)
  • TABLE 25. EUROPE IOVERSOL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 26. EUROPE IOVERSOL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 27. FRANCE IOVERSOL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 28. FRANCE IOVERSOL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 29. GERMANY IOVERSOL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 30. GERMANY IOVERSOL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 31. ITALY IOVERSOL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 32. ITALY IOVERSOL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 33. SPAIN IOVERSOL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 34. SPAIN IOVERSOL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 35. UK IOVERSOL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 36. UK IOVERSOL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 37. RUSSIA IOVERSOL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 38. RUSSIA IOVERSOL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 39. REST OF EUROPE IOVERSOL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 40. REST OF EUROPE IOVERSOL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 41. ASIA-PACIFIC IOVERSOL, BY REGION, 2025-2033 ($MILLION)
  • TABLE 42. ASIA-PACIFIC IOVERSOL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 43. ASIA-PACIFIC IOVERSOL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 44. CHINA IOVERSOL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 45. CHINA IOVERSOL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 46. JAPAN IOVERSOL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 47. JAPAN IOVERSOL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 48. INDIA IOVERSOL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 49. INDIA IOVERSOL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 50. SOUTH KOREA IOVERSOL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 51. SOUTH KOREA IOVERSOL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 52. AUSTRALIA IOVERSOL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 53. AUSTRALIA IOVERSOL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 54. THAILAND IOVERSOL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 55. THAILAND IOVERSOL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 56. MALAYSIA IOVERSOL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 57. MALAYSIA IOVERSOL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 58. INDONESIA IOVERSOL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 59. INDONESIA IOVERSOL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 60. REST OF ASIA PACIFIC IOVERSOL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 61. REST OF ASIA PACIFIC IOVERSOL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 62. LAMEA IOVERSOL, BY REGION, 2025-2033 ($MILLION)
  • TABLE 63. LAMEA IOVERSOL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 64. LAMEA IOVERSOL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 65. BRAZIL IOVERSOL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 66. BRAZIL IOVERSOL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 67. SOUTH AFRICA IOVERSOL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 68. SOUTH AFRICA IOVERSOL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 69. SAUDI ARABIA IOVERSOL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 70. SAUDI ARABIA IOVERSOL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 71. UAE IOVERSOL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 72. UAE IOVERSOL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 73. ARGENTINA IOVERSOL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 74. ARGENTINA IOVERSOL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 75. REST OF LAMEA IOVERSOL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 76. REST OF LAMEA IOVERSOL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 77. LIEBEL-FLARSHEIM COMPANY LLC: KEY EXECUTIVES
  • TABLE 78. LIEBEL-FLARSHEIM COMPANY LLC: COMPANY SNAPSHOT
  • TABLE 79. LIEBEL-FLARSHEIM COMPANY LLC: OPERATING SEGMENTS
  • TABLE 80. LIEBEL-FLARSHEIM COMPANY LLC: PRODUCT PORTFOLIO
  • TABLE 81. LIEBEL-FLARSHEIM COMPANY LLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 82. GUERBET: KEY EXECUTIVES
  • TABLE 83. GUERBET: COMPANY SNAPSHOT
  • TABLE 84. GUERBET: OPERATING SEGMENTS
  • TABLE 85. GUERBET: PRODUCT PORTFOLIO
  • TABLE 86. GUERBET: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 87. JIANGSU HENGRUI MEDICINE CO.: KEY EXECUTIVES
  • TABLE 88. JIANGSU HENGRUI MEDICINE CO.: COMPANY SNAPSHOT
  • TABLE 89. JIANGSU HENGRUI MEDICINE CO.: OPERATING SEGMENTS
  • TABLE 90. JIANGSU HENGRUI MEDICINE CO.: PRODUCT PORTFOLIO
  • TABLE 91. JIANGSU HENGRUI MEDICINE CO.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 92. MALLINCKRODT PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 93. MALLINCKRODT PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 94. MALLINCKRODT PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 95. MALLINCKRODT PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 96. MALLINCKRODT PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 97. ULTRAJECT: KEY EXECUTIVES
  • TABLE 98. ULTRAJECT: COMPANY SNAPSHOT
  • TABLE 99. ULTRAJECT: OPERATING SEGMENTS
  • TABLE 100. ULTRAJECT: PRODUCT PORTFOLIO
  • TABLE 101. ULTRAJECT: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 102. CHINA RESOURCES PHARMACEUTICAL (SHANGHAI) CO.,: KEY EXECUTIVES
  • TABLE 103. CHINA RESOURCES PHARMACEUTICAL (SHANGHAI) CO.,: COMPANY SNAPSHOT
  • TABLE 104. CHINA RESOURCES PHARMACEUTICAL (SHANGHAI) CO.,: OPERATING SEGMENTS
  • TABLE 105. CHINA RESOURCES PHARMACEUTICAL (SHANGHAI) CO.,: PRODUCT PORTFOLIO
  • TABLE 106. CHINA RESOURCES PHARMACEUTICAL (SHANGHAI) CO.,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 107. HB OCEAN: KEY EXECUTIVES
  • TABLE 108. HB OCEAN: COMPANY SNAPSHOT
  • TABLE 109. HB OCEAN: OPERATING SEGMENTS
  • TABLE 110. HB OCEAN: PRODUCT PORTFOLIO
  • TABLE 111. HB OCEAN: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 112. NOVALEK PHARMACEUTICALS PVT. LTD.: KEY EXECUTIVES
  • TABLE 113. NOVALEK PHARMACEUTICALS PVT. LTD.: COMPANY SNAPSHOT
  • TABLE 114. NOVALEK PHARMACEUTICALS PVT. LTD.: OPERATING SEGMENTS
  • TABLE 115. NOVALEK PHARMACEUTICALS PVT. LTD.: PRODUCT PORTFOLIO
  • TABLE 116. NOVALEK PHARMACEUTICALS PVT. LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 117. STELLENCE PHARMSCIENCE PVT. LTD.: KEY EXECUTIVES
  • TABLE 118. STELLENCE PHARMSCIENCE PVT. LTD.: COMPANY SNAPSHOT
  • TABLE 119. STELLENCE PHARMSCIENCE PVT. LTD.: OPERATING SEGMENTS
  • TABLE 120. STELLENCE PHARMSCIENCE PVT. LTD.: PRODUCT PORTFOLIO
  • TABLE 121. STELLENCE PHARMSCIENCE PVT. LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 122. A.S. JOSHI AND COMPANY: KEY EXECUTIVES
  • TABLE 123. A.S. JOSHI AND COMPANY: COMPANY SNAPSHOT
  • TABLE 124. A.S. JOSHI AND COMPANY: OPERATING SEGMENTS
  • TABLE 125. A.S. JOSHI AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 126. A.S. JOSHI AND COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL IOVERSOL MARKET SEGMENTATION
  • FIGURE 2. GLOBAL IOVERSOL MARKET
  • FIGURE 3. SEGMENTATION IOVERSOL MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN IOVERSOL MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALIOVERSOL MARKET
  • FIGURE 11. IOVERSOL MARKET SEGMENTATION, BY BY TYPE
  • FIGURE 12. IOVERSOL MARKET FOR IOVERSOL 34% INJECTABLE SOLUTION (OPTIRAY 160), BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. IOVERSOL MARKET FOR IOVERSOL 51% INJECTABLE SOLUTION (OPTIRAY 240), BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. IOVERSOL MARKET FOR IOVERSOL 64% INJECTABLE SOLUTION (OPTIRAY 300), BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. IOVERSOL MARKET FOR IOVERSOL 68% INJECTABLE SOLUTION (OPTIRAY 320), BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. IOVERSOL MARKET FOR IOVERSOL 74% INJECTABLE SOLUTION (OPTIRAY 350), BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. IOVERSOL MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 18. IOVERSOL MARKET FOR X-RAY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. IOVERSOL MARKET FOR CT SCAN, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. IOVERSOL MARKET FOR BRAIN DISORDERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. IOVERSOL MARKET FOR BLOOD VESSEL DISORDERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 22. IOVERSOL MARKET FOR HEART DISORDERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 23. IOVERSOL MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 24. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 25. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 26. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 27. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 28. COMPETITIVE DASHBOARD
  • FIGURE 29. COMPETITIVE HEATMAP: IOVERSOL MARKET
  • FIGURE 30. TOP PLAYER POSITIONING, 2024
  • FIGURE 31. LIEBEL-FLARSHEIM COMPANY LLC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 32. LIEBEL-FLARSHEIM COMPANY LLC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 33. LIEBEL-FLARSHEIM COMPANY LLC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 34. GUERBET: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 35. GUERBET: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 36. GUERBET: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 37. JIANGSU HENGRUI MEDICINE CO.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 38. JIANGSU HENGRUI MEDICINE CO.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 39. JIANGSU HENGRUI MEDICINE CO.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 40. MALLINCKRODT PHARMACEUTICALS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 41. MALLINCKRODT PHARMACEUTICALS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 42. MALLINCKRODT PHARMACEUTICALS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 43. ULTRAJECT: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 44. ULTRAJECT: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 45. ULTRAJECT: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 46. CHINA RESOURCES PHARMACEUTICAL (SHANGHAI) CO.,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 47. CHINA RESOURCES PHARMACEUTICAL (SHANGHAI) CO.,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 48. CHINA RESOURCES PHARMACEUTICAL (SHANGHAI) CO.,: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 49. HB OCEAN: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 50. HB OCEAN: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 51. HB OCEAN: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 52. NOVALEK PHARMACEUTICALS PVT. LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 53. NOVALEK PHARMACEUTICALS PVT. LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 54. NOVALEK PHARMACEUTICALS PVT. LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 55. STELLENCE PHARMSCIENCE PVT. LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 56. STELLENCE PHARMSCIENCE PVT. LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 57. STELLENCE PHARMSCIENCE PVT. LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 58. A.S. JOSHI AND COMPANY: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 59. A.S. JOSHI AND COMPANY: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 60. A.S. JOSHI AND COMPANY: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Global Ioversol Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved